Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 2 of 4

Direct-acting hepatitis C antivirals begin to have an impact

Following the introduction of newer, all oral, direct-acting antivirals (DAAs) in 2014, the number of patients starting treatment has increased by almost 90%, which may be responsible for the fall in end-stage liver disease (ESLD)- and hepatocellular carcinoma (HCC)-related deaths seen over the past two years.